CALCIUM CHANNEL BLOCKERS IN BREAST CANCER ETIOLOGY

描述：(改编自申请人摘要)。尽管超过三分之一的人 在所有65-79岁的女性中被诊断为乳腺癌的人很少 流行病学研究主要集中在女性乳腺癌上。 这个年龄的人。这个年龄段的女性通常也患有高血压或 冠状动脉疾病和钙通道阻滞剂(CCB)通常用于 治疗这两种情况中的任何一种。最近的两项研究尚未发表， 在65岁及以上的女性中，表明使用CCB的女性可能处于 增加患乳腺癌的风险。这一可疑的关联被给出 通过观察药理阻滞剂的生物学合理性 钙通道可以抑制细胞凋亡(程序性细胞死亡)， 生物体清除不需要的细胞的过程(例如，癌前病变， 启动、损坏、过度)。从这个意义上说，CCB可能是癌症 推动者。 该申请提出了一项针对1000名年龄在65岁至79岁之间的女性的病例对照研究， 居住在华盛顿州金县的哪些人正在接受医疗保健融资 管理(HCFA)磁带，以及被诊断为首次入侵的人 1997年1月1日至12月31日期间的乳腺癌， 1999年。这些女性关于吸毒和吸毒的个人采访回应 其他已知的乳腺癌危险因素将与对照组进行比较。 由1,000名未患乳腺癌的妇女组成的小组将通过 HCFA的录像带。根据初步研究和来自中国的证据 对细胞的体外研究表明，CCBS的使用增加了 老年女性患乳腺癌的风险。 该计划是评估钙拮抗剂是否用于治疗 高血压和心血管疾病促进老年女性患乳腺癌 65-79岁，以及任何一种钙通道阻滞剂是否比 与乳腺癌相关的类型比其他类型更多。因为没有研究表明 评估了雌激素和孕激素联合治疗的现在或过去的使用情况 这个年龄段的一大群女性，同时使用激素替代 这些妇女的治疗(HRT)可能会影响拟议的风险估计 与CCBS相关的数据也将收集和分析在其他 频繁用药(如西咪替丁、抗抑郁药、降脂药) 这个年龄段的女性使用。

DESCRIPTION: (Adapted from Applicant's Abstract). Although over one-third of all breast cancers are diagnosed among women aged 65-79 years, little epidemiologic research has specifically focussed on breast cancer in women of this age. Women of this age also commonly suffer from hypertension or coronary disease, and calcium channel blockers (CCBs) are often used to treat either of these conditions. Two recent studies, yet to be published, of women aged 65 and older, suggest that women who use CCBs may be at an increased risk of breast cancer. This suspected association is given biological plausibility by the observation that pharmacological blockade of the calcium channels can inhibit apoptosis (programmed cell death), the process whereby organisms eliminate unwanted cells (e.g., preneoplastic, initiated, damaged, excessive). In this sense, CCBs may be cancer promoters. The application proposes a case-control study of 1,000 women, aged 65-79, who reside in King County, Washington, who are on the Health Care Financing Administration (HCFA) tapes, and who are diagnosed with their first invasive breast cancer during the time period of January 1, 1997 through December 31, 1999. The personal interview responses of these women about drug use and other known risk factors for breast cancer will be compared to a control group of 1,000 women without breast cancer who will be identified through the HCFA tapes. Based on the preliminary studies and the evidence from in vitro studies on cells, it is posited that the use of CCBs increases the risk of breast cancer in older women. The plan is to assess whether calcium antagonists used in the treatment of hypertension and cardiovascular diseases promote breast cancer in women aged 65-79 years, and whether any one type of calcium channel blocker is more related to breast cancer than the other types. Since no studies have assessed present or past use of combined estrogen-progestin therapy in a large group of women this age, and the concurrent use of hormone replacement therapy (HRT) by these women may affect the proposed estimates of risk associated with CCBs, data will also be collected and analyzed on other drugs (viz., cimetidine, anti-depressants, lipid lowering drugs) frequently used by women in this age group.